{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Background+regimen&page=2",
    "query": {
      "intervention": "Background regimen",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Background+regimen&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T01:08:23.650Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06749054",
      "title": "Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Oral Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "Optimized Background Regimen (OBR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-03-26",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06749054"
    },
    {
      "nct_id": "NCT00008528",
      "title": "T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Enfuvirtide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 525,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008528"
    },
    {
      "nct_id": "NCT01026727",
      "title": "A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MPC-4326 plus a 2-3 drug optimized background regimen (OBR)",
          "type": "DRUG"
        },
        {
          "name": "3-4 commercially available antiretroviral drugs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2009-11",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2010-06-14",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 21,
      "location_summary": "Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01026727"
    },
    {
      "nct_id": "NCT00634933",
      "title": "Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "TRU-015",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2008-03",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-03-11",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634933"
    },
    {
      "nct_id": "NCT05771480",
      "title": "Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + cisplatin + S-1",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + S-1",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + cisplatin + albumin-bound paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 142,
      "start_date": "2023-08-16",
      "completion_date": "2026-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 4,
      "location_summary": "Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05771480"
    },
    {
      "nct_id": "NCT03657160",
      "title": "Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hematopoietic Stem Cells"
      ],
      "interventions": [
        {
          "name": "Vedolizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 343,
      "start_date": "2019-02-06",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657160"
    },
    {
      "nct_id": "NCT00665561",
      "title": "Prospective Observational Epidemiologic Study of Maraviroc's Safety",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Maraviroc along with an optimized background antiretroviral drug regimen",
          "type": "DRUG"
        },
        {
          "name": "Optimized background antiretroviral drug regimen without maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2008-03-31",
      "completion_date": "2019-02-14",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 145,
      "location_summary": "Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00665561"
    },
    {
      "nct_id": "NCT00540449",
      "title": "TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "HIV-1",
        "Human Immunodeficiency Virus Type 1"
      ],
      "interventions": [
        {
          "name": "TMC278",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec Pharmaceuticals, Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 694,
      "start_date": "2008-05",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2016-03-29",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00540449"
    },
    {
      "nct_id": "NCT01266902",
      "title": "A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 482,
      "start_date": "2011-02",
      "completion_date": "2020-02",
      "has_results": true,
      "last_update_posted_date": "2021-03-04",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 29,
      "location_summary": "Beverly Hills, California • Long Beach, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266902"
    },
    {
      "nct_id": "NCT03175367",
      "title": "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evinacumab",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Background Lipid Modifying Therapy (LMT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 272,
      "start_date": "2017-11-10",
      "completion_date": "2020-12-14",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-09-20T01:08:23.650Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175367"
    }
  ]
}